Novartis

Chutes & Ladders—Califf’s post-FDA role at Duke, PCORI-backed foundation

EuroBiotech Report: AstraZeneca rejection, Novartis phase 3 fail, $30M round, BioLineRx and Pierre Fabre

Lilly gets positive abemaciclib phase 3 data, plots 2017 NDA

Astex bags milestone after Novartis cancer drug approved

EuroBiotech—More​​​ ​​​Articles​​​ ​​​of​​​ ​​​Note